Robust IPO issuance in 2026, with 253 traditional offerings completed year-to-date through early October and $156 billion in proceeds already raised—second only to 2021 on deal value—reflects strong equity market demand and a deep pipeline of private companies seeking liquidity. Recent S-1 filings and pricings, including biotech names like TRex Bio and Iambic Therapeutics alongside SPAC activity, underscore sustained risk appetite amid favorable Treasury yields and equity valuations. The market’s focus centers on Anthropic’s anticipated November debut, potentially the largest ever at up to $100 billion, which could unlock further calendar activity before year-end; OpenAI has shifted to 2027. Traders monitor upcoming economic data releases and Fed communications for any shifts in rate expectations that could influence issuance windows.